Outcome of Patients Treated by Intravitreal Injections During the COVID-19 Lockdown: An Institutional Experience

References

• Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144–1167. doi:10.1136/bjophthalmol-2014-305702.
   PubMed Web of Science ®Google Scholar
• Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management. Indian J Ophthalmol. 2018;66(12):1736–1750. doi:10.4103/ijo.IJO_1240_18.
   PubMed Web of Science ®Google Scholar
• McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski J, Nguyen H, Wong T. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1113–1123.e15. doi:10.1016/j.ophtha.2010.01.060.
   PubMed Web of Science ®Google Scholar
• Chong Teo KY, Saxena N, Gan A, Wong TY, Gillies MC, Chakravarthy U, Cheung CM. Detrimental Effect of Delayed Re-treatment of Active Disease on Outcomes in Neovascular Age-Related Macular Degeneration: the RAMPS Study. Ophthalmol Retina. 2020;4(9):871–880. doi:10.1016/j.oret.2020.03.017.
   PubMedGoogle Scholar
• Stone LG, Devenport A, Stratton IM, Talks JS. Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19. Graefes Arch Clin Exp Ophthalmol. 2020;258(12):2639–2645. doi:10.1007/s00417-020-04849-8.
   PubMed Web of Science ®Google Scholar
• Borrelli E, Grosso D, Vella G, Sacconi R, Querques L, Zucchiatti I, Prascina F, Bandello F, Querques G. Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let’s be ready for a plausible “rebound effect. Graefes Arch Clin Exp Ophthalmol. 2020;258(12):2655–2660. doi:10.1007/s00417-020-04858-7.
   PubMed Web of Science ®Google Scholar
• Viola F, Milella P, Pozzo Giuffrida F, Ganci S, Invernizzi A. IMPACT OF CORONAVIRUS DISEASE PANDEMIC ON INTRAVITREAL INJECTIONS TREATMENT FOR MACULAR DISEASES: report From a Referral Hospital in Milan. Retina. 2021;41(4):701–705. doi:10.1097/IAE.0000000000002941.
   PubMed Web of Science ®Google Scholar
• Moussa M, Elshorbagy MS, Emarah A, Gaber R, Moussa OM, El-Bradey M, Alagorie AR, Sorour O. Intravitreal injections of anti-VEGF agents during COVID-19 pandemic: clinical audit from Tanta University Hospital. Int Ophthalmol. 2021;41(4):1437–1443. doi:10.1007/s10792-021-01719-y.
   PubMed Web of Science ®Google Scholar
• Sevik MO, Aykut A, Özkan G, Dericioğlu V, Şahin Ö. The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol. Int Ophthalmol. 2021;41(9):2951–2961. doi:10.1007/s10792-021-01854-6.
   PubMed Web of Science ®Google Scholar
• Uzlu D, Erdol H, Kola M, Gunay M. Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. Beyoglu Eye J. 2022;7(1):47–53.
   PubMedGoogle Scholar
• Yang KB, Feng H, Zhang H. Effects of the COVID-19 Pandemic on Anti-vascular Endothelial Growth Factor Treatment in China. Front Med (Lausanne)). 2020;7:576275. doi:10.3389/fmed.2020.576275.
   PubMed Web of Science ®Google Scholar
• Leng T, Gallivan MD, Kras A, Lum F, Roe MT, Li C, Parke DW, Schwartz SD. Ophthalmology and COVID-19: the Impact of the Pandemic on Patient Care and Outcomes: an IRIS® Registry Study. Ophthalmology. 2021;128(12):1782–1784. doi:10.1016/j.ophtha.2021.06.011.
   PubMed Web of Science ®Google Scholar
• Arruabarrena C, Montejano-Milner R, de Aragón F, Allendes G, Teus MA. Results of the treatment of patients with exudative AMD during the COVID-19 pandemic. Arch Soc Esp Oftalmol. 2022;97(4):184–190. doi:10.1016/j.oftal.2021.02.012.
   Google Scholar
• Billioti de Gage S, Drouin J, Desplas D, Cuenot F, Dray-Spira R, Weill A, Zureik M. Intravitreal Anti-Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic. JAMA Ophthalmol. 2021;139(2):240–242. doi:10.1001/jamaophthalmol.2020.5594.
   PubMed Web of Science ®Google Scholar
• Wasser LM, Weill Y, Brosh K, Magal I, Potter M, Strassman I, Gelman E, Koslowsky M, Zadok D, Hanhart J. The Impact of COVID-19 on Intravitreal Injection Compliance. SN Compr Clin Med. 2020;2(12):2546–2549. doi:10.1007/s42399-020-00614-4.
   PubMedGoogle Scholar
• Sekeroglu MA, Kilinc Hekimsoy H, Horozoglu Ceran T, Doguizi S. Treatment of neovascular age related macular degeneration during COVID-19 pandemic: the short term consequences of unintended lapses. Eur J Ophthalmol. 2021; 32(2):11206721211010612.
   Web of Science ®Google Scholar
• Zhao X, Meng L, Luo M, Yu W, Min H, Dai R, Koh A, Chen Y. The influence of delayed treatment due to COVID-19 on patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Ther Adv Chronic Dis. 2021;12:204062232110263. 20406223211026388. doi:10.1177/20406223211026389.
   Web of Science ®Google Scholar
• Hanhart J, Wiener R, Totah H, Gelman E, Weill Y, Abulafia A, Zadok D. Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2022;260(6):1907–1914. doi:10.1007/s00417-021-05505-5.
   PubMed Web of Science ®Google Scholar
• Borrelli E, Grosso D, Vella G, Sacconi R, Battista M, Querques L, Zucchiatti I, Prascina F, Bandello F, Querques G. Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol. 2020;258(12):2621–2628. doi:10.1007/s00417-020-04955-7.
   PubMed Web of Science ®Google Scholar
• Jiang B, Gao L, Dong S, Hou Q, Sun M, Zhang J, Yu H, Zhang Z, Sun D. The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens. Adv Ther. 2022;39(4):1568–1581. doi:10.1007/s12325-021-01993-3.
   PubMed Web of Science ®Google Scholar
• Szegedi S, Ebner C, Miháltz K, Wachter T, Vécsei-Marlovits PV. Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration. BMC Ophthalmol. 2022;22(1):228. doi:10.1186/s12886-022-02453-4.
   PubMed Web of Science ®Google Scholar
• Brar M, Grewal SPS, Grewal DS, Sharma M, Dogra MR. Impact of COVID-19-related lockdown on retinal disorders treated with intravitreal injections. Oman J Ophthalmol. 2022;15(2):168–174.
   PubMedGoogle Scholar
• Valverde-Megías A, Rego-Lorca D, Fernández-Vigo JI, Murciano-Cespedosa A, Megías-Fresno A, García-Feijoo J. Effect of COVID-19 Lockdown in Spain on Structural and Functional Outcomes of Neovascular AMD Patients. JCM. 2021;10(16):3551. doi:10.3390/jcm10163551.
   Google Scholar
• Tsiropoulos GN, Vallee R, Gallo Castro D, Ambresin A. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: a retrospective study of assessment of functional and structural outcomes. J Fr Ophtalmol. 2022;45(8):852–859. doi:10.1016/j.jfo.2022.05.005.
   PubMed Web of Science ®Google Scholar
• Yeter DY, Dursun D, Bozali E, Ozec AV, Erdogan H. Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment. J Fr Ophtalmol. 2021;44(3):299–306. doi:10.1016/j.jfo.2021.02.001.
   PubMed Web of Science ®Google Scholar
• Navarrete A, Vofo B, Matos K, Rivera A, Chowers I, Levy J. The detrimental effects of delayed intravitreal anti-VEGF therapy for treating retinal pathology: lessons from a forced test-case. Graefes Arch Clin Exp Ophthalmol. 2022;260(7):2201–2208. doi:10.1007/s00417-021-05549-7.
   PubMed Web of Science ®Google Scholar
• Zhou P, Gao J, Huang X, Staggers KA, Biggerstaff K, Orengo-Nania S, Channa R. Impact of the COVID-19 pandemic on visual outcomes of diabetic macular edema patients at a tertiary care veterans affairs center. J Diabetes Metab Disord. 2022;21(1):759–768. doi:10.1007/s40200-022-01049-5.
   PubMed Web of Science ®Google Scholar
• Hurand V, Ducloyer JB, Baudin F, Aho S, Weber M, Kodjikian L, Devin F, Gabrielle PH, Creuzot-Garcher C, Massin P, CFSR Research Net IMPACT study: impact of adherence to anti-VEGF intravitreal injections for macular disease during COVID 19-related confinement in France. Acta Ophthalmol. 2023;101(1):91–99. doi:10.1111/aos.15206.
   PubMed Web of Science ®Google Scholar
• Khodriss C, El Harch I, Bennis A, Chraibi F, El Fakir S, Abdellaoui M, Tachfouti N, Andaloussi IB. [Impact of the SARS-CoV-2 pandemic on diabetic macular edema and prognostic factors]. J Fr Ophtalmol. 2021;44(9):1313–1318. doi:10.1016/j.jfo.2021.07.003.
   PubMedGoogle Scholar
• Douglas VP, Douglas KAA, Vavvas DG, Miller JW, Miller JB. Short- and long-term visual outcomes in patients receiving intravitreal injections: the impact of the coronavirus 2019 disease (covid-19)-related Lockdown. JCM. 2022;11(8):2097. doi:10.3390/jcm11082097.
   Google Scholar
• Song W, Singh RP, Rachitskaya AV. The effect of delay in care among patients requiring intravitreal injections. Ophthalmol Retina. 2021;5(10):975–980. doi:10.1016/j.oret.2020.12.020.
   PubMedGoogle Scholar
• Kim JG, Kim YC, Kang KT. Impact of delayed intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) therapy due to the coronavirus disease pandemic on the prognosis of patients with neovascular age-related macular degeneration. JCM. 2022;11(9):2321. doi:10.3390/jcm11092321.
   Google Scholar
• Rush RB, Rush SW. Outcomes in patients resuming intravitreal anti-vascular endothelial growth factor therapy following treatment delay during the coronavirus-19 pandemic. Retina. 2021;41(12):2456–2461. doi:10.1097/IAE.0000000000003276.
   PubMed Web of Science ®Google Scholar
• Rego-Lorca D, Valverde-Megías A, Fernández-Vigo JI, Oribio-Quinto C, Murciano-Cespedosa A, Sánchez-Quirós J, Donate-López J, García-Feijóo J. Long-term consequences of COVID-19 lockdown in neovascular AMD patients in spain: structural and functional outcomes after 1 year of standard follow-up and treatment. JCM. 2022;11(17):5063. doi:10.3390/jcm11175063.
   Google Scholar
• Rothaus K, Kintzinger K, Heimes-Bussmann B, Faatz H, Lommatzsch AP. Impact of the COVID 19 pandemic on treatment of nAMD via a portal-based collaboration. Klin Monbl Augenheilkd. 2022.
   Web of Science ®Google Scholar
• Groppe M, Bindra MS. Restructuring wet age-related macular degeneration services during the COVID-19 pandemic to allow Social Distancing Outpatient Clinics (SDOC). Clin Ophthalmol. 2021;15:651–659. doi:10.2147/OPTH.S269596.
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Loewenstein A, Eldem B, Joussen AM, Koh A, Lambrou GN, Lanzetta P, Li X, Lövestam-Adrian M, Navarro R, et al. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol. 2020;258(6):1149–1156. doi:10.1007/s00417-020-04703-x.
   PubMed Web of Science ®Google Scholar